Antimetabolites: A new perspective

Drug Discovery Today: Therapeutic Strategies

Volumn 2, Issue 4, 2005, Pages 337-342

  Cole, Peter D ^a   Zebala, John A ^b   Kamen, Barton A ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b SYNTRIX BIOSYSTEMS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMINOPTERIN; AMSACRINE; ANTIANDROGEN; ANTIESTROGEN; ANTIMETABOLITE; AZACITIDINE; CAPECITABINE; CLADRIBINE; CLOFARABINE; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FOLIC ACID ANTAGONIST; HISTONE DEACETYLASE INHIBITOR; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NELARABINE; NUCLEOSIDE ANALOG; PEMETREXED; PENTOSTATIN; PRODRUG; PURINE DERIVATIVE; RALTITREXED; RETINOID; TIOGUANINE;

ARTICLE; CELL METABOLISM; CHEMOTHERAPY; DRUG APPROVAL; DRUG STRUCTURE; METABOLOMICS;

EID: 31044455727     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2005.11.004     Document Type: Review

References (28)

1. G.B. Elion The purine path to chemotherapy Science 244 1989 41-47
2. P. Frost and B.A. Kamen The bullseye of cancer therapy: A moving target Curr. Opin. Pharmacol. 3 2003 335-337
3. H.M.G. Cohen CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma Br. J. Cancer 92 2005 1593-1598
4. Z. Zhu et al. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro Cancer Res. 65 2005 7023-7030
5. S. Gottschalk et al. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells Clin. Cancer Res. 10 2004 6661-6668
6. G. Te Kronnie et al. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition Int. J. Mol. Med. 14 2004 373-382
7. Nat. Rev. Drug Discov. 2005; 4(5):S6-S20.
8. ≤ during weekly therapy Cancer Chemother. Pharmacol. 17 2005 1-9
9. P.D. Cole et al. Phase II trial of oral aminopterin for adults and children with refractory acute leukemia Clin. Cancer Res. 11 2005 8089-8096
10. D.B. Kell Metabolomics, machine learning and modelling: Towards an understanding of the language of cells Biochem. Soc. Trans. 33 2005 520-524
11. S.G. Villas-Bôas et al. Metabolomics or metabolite profiles Trends Biotechnol. 23 2005 385-386
12. Y. Yang et al. Integration of metabolic networks and gene expression in virtual reality Bioinformatics 21 2005 3645-3650
13. G. Weber Reciprocal regulation: Recognition of pattern of gene expression in cancer cells Adv. Enzyme Regul. 42 2002 83-100
14. J.H. Saiki et al. 5-Azacytidine in acute leukaemia Cancer 42 1978 2111-2114
15. B.A. Kamen et al. Chemotherapeutic agents: Folic acid antagonists In: J.F. Holland ed. Cancer Medicine 2003 Williams and Wilkins 727-738
16. C.J. Allegra et al. Evidence for direct inhibition of de novo purine synthesis in human MCF-7 breast cells as a principal mode of metabolic inhibition by methotrexate J. Biol. Chem. 262 1987 13520-13526
17. H. Elnakat and M. Ratnam Distribution, functionality and gene regulation of folate receptor isoforms: Implications in targeted therapy Adv. Drug Deliv. Rev. 56 2004 1067-1084
18. S. Chattopadhyay et al. Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA interference, on the activity of the new generation antifolate pemetrexed in HeLa cells Clin. Cancer Res. 10 2004 7986-7993
19. S. Farber et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist 4-aminopteroylglutamic acid (aminopterin) N. Engl. J. Med. 238 1948 787-793
20. T.A. Garrow et al. Expression cloning of a human cDNA encoding folylpoly(gamma-glutamate) synthetase and determination of its primary structure Proc. Natl. Acad. Sci. U S A 89 1992 9151-9155
21. A.S. Smith et al. A case for the use of aminopterin in treatment of patients with leukemia based upon metabolic studies of blasts in vitro Clin. Cancer Res. 2 1996 69-73
22. H. Refsum et al. Plasma homocysteine in children with acute lymphoblastic leukemia change's during a chemotherapeutic regimen including methotrexate Cancer Res. 51 1991 828-835
23. B.N. Cronstein et al. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation J. Clin. Invest. 92 1993 2675-2682
24. H. Wang et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine J. Biol. Chem. 272 1997 25380-25385
25. A.M. Winter-Vann et al. Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate Proc. Natl. Acad. Sci. 100 2003 6529-6534
26. M.R. Phillips Methotrexate and Ras methylation: A new trick for an old drug? Science 225 2004 13
27. M. Karin Inflammation and cancer: Long reach of Ras Nat. Med. 11 2005 20-21
28. C. Haran Vince Devita: The view from the top Cancer World 6 2005 38-42